Print Issue: May 01, 2007

Early Zoledronic Acid Use Beneficial

Treatment with zoledronic acid (Zometa) before onset of skeletal morbidity may lower the risk of skeletal-related events (SRE) and prolong the time to the first SRE in men with bone metastases from prostate cancer, according to German researchers.

Next post in Commentary